Aethlon reports Q2 net loss $3.8M; terminates COVID trial, launches Australia sub

AETHLON MEDICAL INC

2022-Q2 EPS reported -$0.37

Cash balance $19.6M as of Sep 30, 2022; operating expenses $3.67M, up 71% YoY.
Terminated US COVID trial due to scarce ICU patients; expects $5M savings over 12 months.
Launched wholly owned Australian subsidiary in Oct 2022 to conduct oncology studies.
Dissolved Exosome Sciences, Inc., recording $142K non-cash charge in Q2.
Raised ~$8.9M net proceeds from ATM stock sales in H1 fiscal 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AETHLON MEDICAL INC reported its second quarter ended September 30, 2022 results: net income approximately $3.8 million.

Period: its second quarter ended September 30, 2022
Net income: approximately $3.8 million
Result: reported results

Exact text from the filing

As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-22-007719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.